- Home
- FRPH vs CRGX Comparison
FRPH vs CRGX Comparison
Compare FRPH & CRGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FRPH
- CRGX
- Stock Information
- Founded
- FRPH 1986
- CRGX 2021
- Country
- FRPH United States
- CRGX United States
- Employees
- FRPH N/A
- CRGX N/A
- Industry
- FRPH Real Estate
- CRGX
- Sector
- FRPH Finance
- CRGX
- Exchange
- FRPH Nasdaq
- CRGX Nasdaq
- Market Cap
- FRPH 576.6M
- CRGX 628.6M
- IPO Year
- FRPH N/A
- CRGX 2023
- Fundamental
- Price
- FRPH $30.67
- CRGX $3.76
- Analyst Decision
- FRPH
- CRGX Hold
- Analyst Count
- FRPH 0
- CRGX 7
- Target Price
- FRPH N/A
- CRGX $4.67
- AVG Volume (30 Days)
- FRPH 27.0K
- CRGX 1.9M
- Earning Date
- FRPH 03-05-2025
- CRGX 03-20-2025
- Dividend Yield
- FRPH N/A
- CRGX N/A
- EPS Growth
- FRPH 45.62
- CRGX N/A
- EPS
- FRPH 0.40
- CRGX N/A
- Revenue
- FRPH $31,414,000.00
- CRGX N/A
- Revenue This Year
- FRPH N/A
- CRGX N/A
- Revenue Next Year
- FRPH N/A
- CRGX N/A
- P/E Ratio
- FRPH $76.97
- CRGX N/A
- Revenue Growth
- FRPH 4.04
- CRGX N/A
- 52 Week Low
- FRPH $26.99
- CRGX $3.00
- 52 Week High
- FRPH $33.00
- CRGX $33.92
- Technical
- Relative Strength Index (RSI)
- FRPH 54.78
- CRGX 20.88
- Support Level
- FRPH $30.50
- CRGX $3.00
- Resistance Level
- FRPH $31.39
- CRGX $3.88
- Average True Range (ATR)
- FRPH 0.59
- CRGX 0.92
- MACD
- FRPH 0.11
- CRGX -1.00
- Stochastic Oscillator
- FRPH 69.65
- CRGX 5.99
About FRPH FRP Holdings Inc.
FRP Holdings Inc is a holding company engaged in various real estate businesses. The company's business segments are Leasing and management of commercial properties owned by the company (the Industrial/Commercial Segment); Leasing and management of mining royalty land owned by the company (the Mining Royalty Lands Segment); real property acquisition, entitlement, development and construction for apartment, retail, warehouse, and office buildings either alone or through joint ventures (the Development Segment); ownership, leasing and management of buildings through joint ventures (the Multifamily Segment).
About CRGX CARGO Therapeutics Inc.
Cargo Therapeutics Inc is a clinical-stage biotechnology company positioned to advance next generation, potentially curative cell therapies for cancer patients. It programs, platform technologies, and manufacturing plan are designed to directly address the key limitations of approved cell therapies, including limited durability of effect, suboptimal safety and unreliable supply. The company's program, CRG-022, is a novel CAR T-cell product candidate designed to address resistance mechanisms by targeting CD22, an alternate tumor antigen that is expressed in a vast majority of B-cell malignancies.